Limited Influence of Excipients in Extemporaneous Compounded Suspensions

Hospital Pharmacy
2017, Vol. 52(6) 428–432
© The Author(s) 2017
Reprints and permissions:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/0018578717717393
journals.sagepub.com/home/hpx

Eli Dijkers¹, Valerie Nanhekhan¹, Astrid Thorissen¹,
Diego Marro², and Marta Uriel²

Abstract

Objective: The objective of this study was to identify whether compounding oral suspensions with SyrSpend SF based on tablets or capsules is a suitable alternative for using raw pharmaceutical materials. **Methods:** Suspensions based on 5 different tablets and capsules were studied in SyrSpend SF. The summary of product characteristics of these different tablets and capsules were obtained from the manufacturer. Our hypothesis was that, if the maximum beyond-use date of the study was reached, the excipient did not seem to have an influence on the stability of the active pharmaceutical ingredient (API) within the studied time frame. **Results:** All excipients used in flecainide acetate, labetalol HCl, and tiagabine HCl tablets as well as in celecoxib and oseltamivir capsules did not seem to influence the beyond-use date of the overall suspension based on SyrSpend SF. **Conclusion:** Although using raw materials as API sources is preferred, oral suspensions with SyrSpend SF prepared from crushed tablets or opened capsules could be a possible alternative. Based on this study, a wide range of different excipients does not seem to impact the beyond-use date of different APIs compounded in SyrSpend SF.

Keywords

compatibility, stability, oral suspension, compounding, excipients

Community and hospital pharmacists are often required to compound extemporaneous oral liquids in case of patients with dose adjustments, for patients unable to swallow oral solid medication or when patients are receiving their medication via an enteral feeding tube.¹ To assure patient safety and compliance, a number of aspects need to be considered, including chemical, physical, and microbiological stability and palatability of the compounded medication.

In practice, due to convenience or availability of raw pharmaceutical ingredients, (hospital) pharmacists often resort to capsules or tablets as the source of their active pharmaceutical ingredient (API). These commercial solid dosage forms are formulated with—among others—excipients promoting dilution, flow and disintegration, colorants, flavors, and binding agents.² Stability of the oral liquid is therefore no longer just determined by the interaction of the API with the vehicle alone, but also by the chemical and physical interaction of the API with the excipients.^{1,3} As formulation of oral liquids is often only partially supported by pharmacopoeia and other scientific evidence, assigning a beyond-use date (BUD) by the (hospital) pharmacist can be challenging.

A wide range of APIs is currently being studied in SyrSpend SF, a commercial oral suspension base. Compatibility results

with SyrSpend SF have been published for more than 70 different APIs.^{4–21} In all of these studies, the compatibility was assessed by measuring the percentage recovery at varying time points throughout a 90-day period at controlled room and/or at controlled refrigerated temperature. The majority of the compatibility studies have been performed with raw pharmaceutical APIs. In case of celecoxib, flecainide acetate, labetalol hydrochloride, oseltamivir phosphate, and tiagabine hydrochloride where no raw pharmaceutical material was available, commercially available tablets or capsules were used. High-performance liquid chromatography with diode array detection was used for both the compatibility study and a forced degradation study. The latter was executed with the aim of identifying all degradation products that may be produced during storage of the samples. All APIs except for

¹Fagron, Rotterdam, The Netherlands

²Universidad San Jorge, Villanueva de Gállego Zaragoza, Spain

Corresponding Author:

Eli Dijkers, Hospital Pharmacist, Global Compounding Knowledge Manager, Fagron BV, Lichtenauerlaan 182, 3062 ME Rotterdam, The Netherlands.

Email: eli.dijkers@fagron.com

Table 1. Summary of all the Excipients Present in the Celecoxib, Flecainide Acetate, Labetalol Hydrochloride, Oseltamivir Phosphate, or Tiagabine Hydrochloride Tablets and Capsules Tested With SyrSpend SF.

Excipient
FD and C Blue 2 (indigo carmine, E132)
Ascorbic acid (E300)
Cellulose microcrystalline (E460)
Corn starch
Carnauba wax
Quinoline Yellow aluminium
Croscarmellose sodium (E468)
Crospovidone
Edible inks
Erythrosine
Gelatin
Hydrogenated vegetable oil (Type I)
Hydroxypropylcellulose (E463)
Hypromellose
Lactose, anhydrous
Lactose, monohydrate
Magnesium stearate
Macrogol 400
Microcrystalline cellulose
Polyethylene glycol
Polysorbate 80 (E433)
Povidone
Pregelatinized starch (derived from maize starch)
Propylene glycol
Red iron oxide (E172)
Saccharose
Shellac
Silica, colloidal anhydrous (E551)
Sodium lauryl sulfate
Sodium starch glycolate
Sodium stearyl fumarate
Sorbitan monolaurate
Stearic acid
Talc
Titanium dioxide (E171)
Black iron oxide (E172)
Red iron oxide (E172)
Quinoline yellow (E104)
Yellow iron oxide (E172)

Note. All APIs showed a full 90-day stability in presence of the excipients listed in the table. This indicates that these excipients do not negatively impact the API stability when compounded in SyrSpend SF. API = active pharmaceutical ingredient.

oseltamivir phosphate were analyzed with the HP Agilent Series 1100; oseltamivir phosphate was studied using a Varian Prostar. Analytical grade chemical reagent and standards were used throughout the study. During validation of the method, linearity, fit, limit of detection (LOD), limit of quantification

(LOQ), and recovery were determined. In the compatibility study, the appropriate amount of API was levigated with SyrSpend SF PH4 (liquid) using geometric dilution to form a smooth suspension. The API concentration was determined in 6-fold at predefined time points until $T = 90$ days. The oral liquid formulation was considered stable when the content was between 90% and 110% of the declared amount.

Although the compatibility studies were set up to determine the BUD of the APIs, we believe that the results can also be used to determine a possible influence of the excipients on the API. We postulated that the presence of excipients either accelerate API degradation or have no influence on API stability. Therefore, if the API in the study reaches the maximal studied BUD, the excipient does not seem to have an influence on the stability of the API within the studied time frame. For the study, Celecoxib (Celebrex) 200 mg capsules were obtained from Pfizer, flecainide acetate (Apocard) 100 mg tablets were obtained from Meda Pharma SAU, labetalol hydrochloride (Trandate) 200 mg tablets were obtained from Kern Pharma, oseltamivir phosphate (Tamiflu) 75 mg capsules were obtained from Roche, and tiagabine hydrochloride (Gabitril) 15 mg oral tablets were obtained from Teva Pharma BV. The list of excipients present in these oral dosage forms were acquired from the manufacturer's summary of product characteristics.²²⁻²⁷

The results of the compatibility studies are summarized in Table 1. The compatibility data show that all of the actives reached a BUD of 90 days,^{4,28} indicating no influence of the excipients present in the tested celecoxib, flecainide acetate, labetalol hydrochloride, oseltamivir phosphate, or tiagabine hydrochloride tablets or capsules.

These results found in SyrSpend SF are in concordance with the results found in published compatibility studies with other vehicles, although in general these APIs show a longer BUD when combined with SyrSpend SF than with the other vehicles (simple syrup, fruit juices, or water). These data are summarized in Table 2. The oseltamivir phosphate results in SyrSpend SF⁴ were published at an intermediate time point (30 days) because of the bird flu epidemic at that time. Consecutive study results have shown a 90 days BUD.²⁹

Summarizing, the data of previously performed compatibility studies indicates that commonly used excipients present in crushed tablets or opened capsules appear to have no distinct influence on the stability of celecoxib, flecainide acetate, labetalol hydrochloride, oseltamivir phosphate, and tiagabine hydrochloride when compounded in SyrSpend SF. This indicates that tablets and capsules could be a possible API source, when no raw pharmaceutical material is available. From this study, it can be concluded that a wide range of different excipients does not seem to impact the maximum BUD of different APIs compounded in SyrSpend SF.

Table 2. Overview of All Celecoxib, Flecainide Acetate, Labetalol Hydrochloride, Oseltamivir Phosphate And Tiagabine Hydrochloride Beyond-Use-Dates Published in the Literature.

Active pharmaceutical ingredient	Excipients present in the commercial dose form	Beyond-use-dates that have previously been published in the literature
Celecoxib	Croscarmellose sodium	90 days ³⁰
	Gelatin	
	Iron oxide E172	
	Lactose monohydrate	
	Magnesium stearate	
	Povidone	
	Propylene glycol	
	Shellac	
	Sodium laurel sulfate	
	Sorbitan monolaurate	
Flecainide acetate	Titanium dioxide E171	45-60 days ^{31,32}
	Croscarmellose sodium	
	Magnesium stearate	
	Maize starch	
Labetalol HCl	Microcrystalline cellulose (E460)	30-60 days ^{33,34}
	Pregelatinized maize starch	
	Carnauba wax	
	Distilled water/coloring agent	
	Erythrosine	
	Hypromellose	
	Hydroxypropyl methylcellulose	
	Macrogol 400	
	Magnesium stearate	
	Methylparaben	
	Microcrystalline cellulose	
	Polyethylene glycol	
	Polyvinylpyrrolidone	
	Pregelatinized starch (derived from maize starch)	
	Propylparaben	
	Quinoline yellow (E104)	
	Saccharose	
	Silica gel	
Oseltamivir phosphate	Sodium starch glycolate	35-92 days ³⁵⁻³⁷
	Tartaric acid	
	Black iron oxide (E172)	
	Croscarmellose sodium	
	FD and C Blue 2 (indigo carmine, E132)	
	Gelatin	
	Povidone	
	Pregelatinized starch (derived from maize starch)	
	Red iron oxide (E172)	
	Shellac	
	Sodium stearyl fumarate	
	Talc	
	Titanium dioxide (E171)	
Tiagabine	Titanium dioxide (E171)	42-70 days ^{38,39}
	Yellow iron oxide (E172)	
	Ascorbic acid (E300)	
	Cellulose, microcrystalline (E460)	
	Crospovidone	
	Hydrogenated vegetable oil (Type I)	
	Hydroxypropylcellulose (E463)	
	Hypromellose	
	Lactose, anhydrous	
	Magnesium stearate	
	Silica, colloidal anhydrous (E551)	
	Starch, pregelatinized (maize)	
	Stearic acid	
	Titanium Dioxide (E171)	

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PACMI is an independent Quality Control Laboratory that has performed the analyses. Eli Dijkers, Valerie Nanhekhan, and Astrid Thorissen are employees of Fagron BV.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was conducted under the sponsorship of Fagron.

References

- Haywood A, Glass BD. Liquid dosage forms extemporaneously prepared from commercially available products—considering new evidence on stability. *J Pharm Pharm Sci*. 2013;16(3):441-455.
- Haywood A, Glass BD. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. *J Pharm Pharm Sci*. 2006;9(3):398-426.
- Bouwman-Boer Y, Fenton-May V, Le Brun P. *Practical pharmaceuticals: An international guideline for the preparation, care and use of medicinal products*. Cham, Switzerland: Springer International Publishing; 2015.
- Voudrie MA, Allen B. Stability of oseltamivir phosphate in SyrSpend SF, cherry syrup, and SyrSpend SF (for reconstitution). *Int J Pharm Compd*. 2010;14(1):82-86.
- Geiger CM, Sorenson B, Whaley P. Stability assessment of 10 active pharmaceutical ingredients compounded in SyrSpend SF. *Int J Pharm Compd*. 2015;19:420-427.
- Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MA, Raposo NR. Feasibility of amlodipine besylate, chloroquine phosphate, dapson, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. *J Pharm Biomed Anal*. 2016;118:105-112.
- Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MAF. Stability of atenolol, clonazepam, dexamethasone, diclofenac sodium, diltiazem, enalapril maleate, ketoprofen, lamotrigine, penicillamine-d, and thiamine in SyrSpend SF PH4 oral suspensions. *Int J Pharm Compd*. 2016;20:167-174.
- Geiger CM, Sorenson B, Whaley PA. Stability of captopril in SyrSpend SF. *Int J Pharm Compd*. 2013;17:336-338.
- Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. *Pharmazie*. 2016;71:185-191.
- Sorenson B, Voudrie MA, Gehrig D. Stability of gabapentin in SyrSpend SF. *Int J Pharm Compd*. 2012;16:347-349.
- Vu NT, Aloumanis V, Ben MJ, et al. Stability of metronidazole benzoate in SyrSpend SF one-step suspension system. *Int J Pharm Compd*. 2008;12:558-564.
- Geiger CM, Sorenson B, Whaley PA. Stability of midazolam in SyrSpend SF and SyrSpend SF cherry. *Int J Pharm Compd*. 2013;17:344-346.
- Whaley PA, Voudrie MA, Sorenson B. Stability of omeprazole in SyrSpend SF Alka (reconstituted). *Int J Pharm Compd*. 2012;16:164-166.
- Geiger CM, Voudrie MA, Sorensen B. Stability of propranolol hydrochloride in SyrSpend SF. *Int J Pharm Compd*. 2012;16:513-515.
- Sorenson B, Whaley P. Stability of rifampin in SyrSpend SF. *Int J Pharm Compd*. 2013;17:162-164.
- Geiger CM, Voudrie MA, Sorenson B. Stability of ursodiol in SyrSpend SF cherry flavored. *Int J Pharm Compd*. 2012;16:510-512.
- Whaley PA, Voudrie MA. Stability of vancomycin in SyrSpend SF. *Int J Pharm Compd*. 2012;16:167-169.
- Voudrie MA, Alexander B, Allen B. Stability of verapamil hydrochloride in SyrSpend SF compared to sorbitol containing syrup and suspending vehicles. *Int J Pharm Compd*. 2011;15:255-258.
- Polonini HC, Loures S, de Araujo ED, Brandão MAF, Ferreira AO. Stability of allopurinol, amitriptyline hydrochloride, carbamazepine, domperidone, isoniazid, ketoconazole, lisinopril, naproxen, paracetamol (acetaminophen), and sertraline hydrochloride in SyrSpend SF PH4 oral suspensions. *Int J Pharm Compd*. 2016;20:426-434.
- Polonini HC, Silva SL, de Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. *Eur J Hosp Pharm*. 2016;23(6):352-358.
- Polonini HC, Silva SL, Loures S, et al. Compatibility of proton pump inhibitors in a preservative-free suspending vehicle [published online ahead of print September 25, 2016]. *Eur J Hosp Pharm*. doi:10.1136/ejhpharm-2016-001034.
- Product information: Celebrex®, 200 mg celecoxib capsules. Pfizer BV, Spain, 2015.
- Product information: Apocard®, flecainide acetate 100 mg tablets. Meda Pharma SAU, Spain, 2015.
- Product information: Trandate®, labetalol hydrochloride 200 mg tablets. Kern Pharma, Spain, 2015.
- Product information: Tamiflu®, oseltamivir phosphate 75 mg capsules. Roche, San Francisco, CA, United States, 2010.
- Product information: Gabitril®, tiagabine hydrochloride 15 mg tablets. Teva Pharma BV, The Netherlands, 2016.
- Summary of product characteristics. <http://www.cbg-meb.nl/geneesmiddeleninformatiebank>. Accessed June 1, 2016.
- Uriel M, Gómez-Rincón C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF: melatonin, glycopyrrolate, cyclosporin, chloral hydrate, flecainide acetate, tiagabine HCl, labetalol HCl, ciprofloxacin HCl, hydrocortisone, itraconazole, celecoxib and spironolactone/hydrochlorothiazide [manuscript submitted for publication].
- Dijkers ECF, Nanhekhan V, Thorissen A. Updated Stability Data for Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil. *Int J Pharm Compd*. 2017;21:240-241.
- Donnelly RF, Pascuet E, Ma C, Vaillancourt R. Stability of celecoxib oral suspension. *Can J Hosp Pharm*. 2009;62(6):465-468.
- Allen LV Jr, Erickson MA. Stability of baclofen, captopril, diltiazem hydrochloride, dipyrindamole, and flecainide acetate in extemporaneously compounded oral liquids. *Am J Health-Syst Pharm*. 1996;53(18):2179-2184.

32. Wiest DB, Garner SS, Pagacz LR, et al. Stability of flecainide acetate in an extemporaneously compounded oral suspension. *Am J Hosp Pharm.* 1992;49:2784-2785.
33. Allen LV Jr, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. *Am J Health-Syst Pharm.* 1996;53(19):2304-2309.
34. Nahata MC. Stability of labetalol hydrochloride in distilled water, simple syrup, and three fruit juices. *Ann Pharmacother.* 1991;25(5):465-469.
35. Winiarski AP, Infeld MH, Tscherne R, et al. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. *J Am Pharm.* 2007;47(6):747-755.
36. Ford SM, Kloessel LG, Grabenstein JD. Stability of oseltamivir in various extemporaneous liquid preparations. *Int J Pharm Compound.* 2007;11:162-174.
37. Albert K, Bockshorn J. Chemical stability of oseltamivir in oral solutions. *Pharmazie.* 2007;62:678-682.
38. Nahata MC, Morosco RS. Stability of tiagabine in two oral liquid vehicles. *Am J Health Syst Pharm.* 2003;60(1):75-77.
39. Haase MR, Khan MA, Bonilla J. Stability of two concentrations of tiagabine in an extemporaneously compounded suspension. *Int J Pharm Compound.* 2003;7:485-489.